[artículo] 
inEuropean Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 378-389

Título :	Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months
Tipo de documento:	texto impreso
Autores:	Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Carole Belaïdi, Autor
Fecha de publicación:	2021
Artículo en la página:	pp. 378-389
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Agomelatina, Depresión, Placebo, Régimen de dosis, Largo plazo
Resumen:	This randomized placebo-controlled “dose relation study” was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 patients entered the extension period),...
Link:	./index.php?lvl=notice_display&id=26620

[artículo] Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months [texto impreso] / Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Carole Belaïdi, Autor . - 2021 . - pp. 378-389.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 378-389

Palabras clave:	Agomelatina, Depresión, Placebo, Régimen de dosis, Largo plazo
Resumen:	This randomized placebo-controlled “dose relation study” was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 patients entered the extension period),...
Link:	./index.php?lvl=notice_display&id=26620